Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor
patients and if that distribution is consistent through repeated scans. This is an RDRC study
- as such, the images obtained for this study cannot be used clinically or shared with
treating oncologists.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yusuf Menda
Collaborators:
Holden Comprehensive Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)